Edition:
United States

Aimmune Therapeutics Inc (AIMT.OQ)

AIMT.OQ on NASDAQ Stock Exchange Global Select Market

22.93USD
3:59pm EST
Change (% chg)

$-0.27 (-1.16%)
Prev Close
$23.20
Open
$23.22
Day's High
$23.53
Day's Low
$22.75
Volume
188,835
Avg. Vol
220,994
52-wk High
$37.80
52-wk Low
$21.31

Latest Key Developments (Source: Significant Developments)

Aimmune Therapeutics Submits BLA To FDA For Ar101 For The Treatment Of Peanut Allergy In Children And Adolescents Ages 4–17
Friday, 21 Dec 2018 04:01pm EST 

Dec 21 (Reuters) - Aimmune Therapeutics Inc ::AIMMUNE THERAPEUTICS SUBMITS BLA TO FDA FOR AR101 FOR THE TREATMENT OF PEANUT ALLERGY IN CHILDREN AND ADOLESCENTS AGES 4–17.  Full Article

Nestle Health Science Us Holdings Inc Reports 18.9 Percent Stake In Aimmune Therapeutics As Of Nov 28
Monday, 3 Dec 2018 02:23pm EST 

Dec 3 (Reuters) - :NESTLE HEALTH SCIENCE US HOLDINGS, INC REPORTS 18.9 PERCENT STAKE IN AIMMUNE THERAPEUTICS INC AS OF NOV 28, 2018 - SEC FILING.NESTLE HEALTH SCIENCE US HOLDINGS, INC - HAD PREVIOSULY REPORTED 15.0 PERCENT STAKE IN AIMMUNE THERAPEUTICS INC AS OF FEB 26, 2018.  Full Article

Aimmune Therapeutics Qtrly Loss Per Share $0.89
Thursday, 8 Nov 2018 04:01pm EST 

Nov 8 (Reuters) - Aimmune Therapeutics Inc ::AIMMUNE THERAPEUTICS ANNOUNCES THIRD QUARTER 2018 FINANCIAL RESULTS AND RECENT CORPORATE HIGHLIGHTS.AIMMUNE THERAPEUTICS INC - AS OF SEPTEMBER 30, 2018, CASH, CASH EQUIVALENTS AND INVESTMENTS TOTALED $255.2 MILLION.AIMMUNE THERAPEUTICS INC QTRLY LOSS PER SHARE $0.89.  Full Article

Aimmune Therapeutics Reports Q1 Loss Per Share $0.92
Tuesday, 8 May 2018 04:01pm EDT 

May 8 (Reuters) - Aimmune Therapeutics Inc ::AIMMUNE THERAPEUTICS ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.92.Q1 EARNINGS PER SHARE VIEW $-0.71 -- THOMSON REUTERS I/B/E/S.  Full Article

Aimmune Therapeutics Qtrly Loss Per Share $0.81
Monday, 12 Mar 2018 08:00am EDT 

March 12 (Reuters) - Aimmune Therapeutics Inc ::AIMMUNE THERAPEUTICS ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS.AIMMUNE THERAPEUTICS INC - QTRLY LOSS PER SHARE $0.81.AIMMUNE THERAPEUTICS INC - PLANNED BLA SUBMISSION ON TRACK FOR YEAR-END 2018.  Full Article

Aimmune Therapeutics Announces Pricing Of Public Offering Of Common Stock
Wednesday, 21 Feb 2018 07:28pm EST 

Feb 21 (Reuters) - Aimmune Therapeutics Inc ::AIMMUNE THERAPEUTICS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.AIMMUNE THERAPEUTICS- ANNOUNCED ‍PRICING OF AN UNDERWRITTEN PUBLIC OFFERING OF 5.5 MILLION SHARES OF ITS COMMON STOCK AT A PRICE TO PUBLIC OF $32.00/SHARE​.  Full Article

Aimmune Therapeutics Announces Proposed Public Offering Of Common Stock
Tuesday, 20 Feb 2018 04:17pm EST 

Feb 20 (Reuters) - Aimmune Therapeutics Inc ::AIMMUNE THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.AIMMUNE THERAPEUTICS - COMMENCED OFFERING OF UP TO $150 MILLION SHARES.AIMMUNE - EXPECTS TO USE PROCEEDS FROM OFFERING TO FUND ONGOING CLINICAL DEVELOPMENT OF AR101.  Full Article

Aimmune Therapeutics' Phase 3 Palisade Trial Of Ar101 Meets Primary Endpoint In Patients With Peanut Allergy
Tuesday, 20 Feb 2018 07:00am EST 

Feb 20 (Reuters) - Aimmune Therapeutics Inc ::AIMMUNE THERAPEUTICS’ PIVOTAL PHASE 3 PALISADE TRIAL OF AR101 MEETS PRIMARY ENDPOINT IN PATIENTS WITH PEANUT ALLERGY.AIMMUNE THERAPEUTICS’ PIVOTAL PHASE 3 PALISADE TRIAL OF AR101 MEETS PRIMARY ENDPOINT IN PATIENTS WITH PEANUT ALLERGY.AIMMUNE THERAPEUTICS-LOWER-BOUND OF 95% CONFIDENCE INTERVAL OF DIFFERENCE BETWEEN TREATMENT ARMS AT PRIMARY ENDPOINT WAS 53.0, GREATLY EXCEEDING PRE-SPECIFIED THRESHOLD OF 15%.AIMMUNE THERAPEUTICS-AMONG PATIENTS AGES 4-17 WHO COMPLETED TREATMENT WITH AR101, 96.3% TOLERATED A 300-MG DOSE OF PEANUT PROTEIN IN EXIT FOOD CHALLENGE.AIMMUNE THERAPEUTICS SAYS 2.4% OF AR101 PATIENTS AGES 4-17 AND 0.8% OF PLACEBO PATIENTS EXPERIENCED SERIOUS ADVERSE EVENTS.  Full Article

Aimmune Extends Supply Agreement With Golden Peanut And Tree Nuts For Experimental Allergy Treatment
Wednesday, 10 Jan 2018 08:00am EST 

Jan 10 (Reuters) - Aimmune Therapeutics Inc ::AIMMUNE THERAPEUTICS BROADENS AND EXTENDS SUPPLY AGREEMENT WITH GOLDEN PEANUT AND TREE NUTS FOR AR101 FOR PEANUT ALLERGY.AIMMUNE THERAPEUTICS INC - ‍NEWLY EXPANDED GLOBAL AGREEMENT SECURES EXCLUSIVE SUPPLY RELATIONSHIP THROUGH 2033​.AIMMUNE THERAPEUTICS INC - AR101 IS CURRENTLY IN PHASE 3 CLINICAL TRIALS, WITH PIVOTAL TOPLINE DATA EXPECTED IN FEBRUARY.AIMMUNE THERAPEUTICS INC - ‍AS PART OF AGREEMENT, AIMMUNE HAS GRANTED ADM A 300,000-SHARE EQUITY STAKE IN AIMMUNE​.AIMMUNE THERAPEUTICS BROADENS AND EXTENDS SUPPLY AGREEMENT WITH GOLDEN PEANUT AND TREE NUTS FOR AR101 FOR PEANUT ALLERGY.AIMMUNE THERAPEUTICS - ‍ AGREEMENT GIVES CO EXCLUSIVE ACCESS TO ADDITIONAL GOLDEN PRODUCTS THAT COULD BE DEVELOPED INTO PEANUT ORAL IMMUNOTHERAPIES​.  Full Article

Aimmune Therapeutics says ‍CEO Stephen Dilly plans to retire by end of 2018​
Monday, 6 Nov 2017 08:30am EST 

Nov 6 (Reuters) - Aimmune Therapeutics Inc :Aimmune Therapeutics Inc announces third quarter 2017 financial results and planned retirement of CEO by the end of 2018.Aimmune Therapeutics Inc - ‍CEO Stephen Dilly plans to retire by end of 2018​.Aimmune Therapeutics Inc - ‍Aimmune will initiate a search for a successor CEO​.Aimmune Therapeutics Inc - ‍Dilly will continue as Aimmune's CEO until his replacement joins company and will be available through a transition period​.Aimmune Therapeutics Inc qtrly ‍on a per share basis, net loss for quarter was $0.63​.Q3 earnings per share view $-0.72 -- Thomson Reuters I/B/E/S.Aimmune Therapeutics Inc - ‍expects last double-blind, placebo-controlled food challenge in phase 3 palisade trial of ar101 will be conducted in Dec. 2017​.Aimmune Therapeutics Inc - ‍cash, cash equivalents, and investments were $212.0 million at Sept 30, 2017, compared to $282.5 million at december 31, 2016​.Aimmune Therapeutics Inc - ‍top-line data from phase 3 palisade trial of ar101 will be available in q1 of 2018​.  Full Article

BRIEF-Aimmune Therapeutics Announces Closing Of $98 Mln Investment By Nestlé Health Science

* AIMMUNE THERAPEUTICS ANNOUNCES CLOSING OF $98 MILLION INVESTMENT BY NESTLÉ HEALTH SCIENCE